The Living Guidelines: Prevention of thromboembolism in patients with atrial fibrillation undergoing cardioversion: Polling Results for CLASS IIa Guidelines
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Any recommendations found on these pages are for education use only. WikiDoc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here. In suggesting edits to the guidelines, WikiDoc suggests that the following classification scheme be used. Read more about the classification scheme used by the ACC / AHA Guidelines Committee here.
Class IIa Guidelines
1. During the first 48 h after onset of AF, the need for anticoagulation before and after cardioversion may be based on the patient’s risk of thromboembolism. (Level of Evidence: C) [1]
<Poll>
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIa Recommendation 1 for pharmacological cardioversion of atrial fibrillation should be:
CLASS I
CLASS IIa
CLASS IIb
CLASS III
</poll>
2. As an alternative to anticoagulation prior to cardioversion of AF, it is reasonable to perform TEE in search of thrombus in the LA or LAA. (Level of Evidence: B) <[1]
<Poll>
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIa Recommendation 2 for pharmacological cardioversion of atrial fibrillation should be:
CLASS I
CLASS IIa
CLASS IIb
CLASS III
</poll>
2a. For patients with no identifiable thrombus, cardioversion is reasonable immediately after anticoagulation with unfractionated heparin (e.g., initiate by intravenous bolus injection and an infusion continued at a dose adjusted to prolong the activated partial thromboplastin time to 1.5 to 2 times the control value until oral anticoagulation has been established with a vitamin K antagonist (e.g., warfarin), as evidenced by an INR equal to or greater than 2.0.). (Level of Evidence: B) [1]
<Poll>
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIa Recommendation 2a for pharmacological cardioversion of atrial fibrillation should be:
CLASS I
CLASS IIa
CLASS IIb
CLASS III
</poll>
2a 1. Thereafter, oral anticoagulation (INR 2.0 to 3.0) is reasonable for a total anticoagulation period of at least 4 wk, as for patients undergoing elective cardioversion. (Level of Evidence: B) [1]
<Poll>
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIa Recommendation 2a-1 for pharmacological cardioversion of atrial fibrillation should be:
CLASS I
CLASS IIa
CLASS IIb
CLASS III
</poll>
2a-2. Limited data are available to support the subcutaneous administration of a low molecular weight heparin in this indication. (Level of Evidence: C) [1]
<Poll>
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIa Recommendation 2a-2 for pharmacological cardioversion of atrial fibrillation should be:
CLASS I
CLASS IIa
CLASS IIb
CLASS III
</poll>
2b. For patients in whom thrombus is identified by TEE, oral anticoagulation (INR 2.0 to 3.0) is reasonable for at least 3 week prior to and 4 week after restoration of sinus rhythm, and a longer period of anticoagulation may be appropriate even after apparently successful cardioversion, because the risk of thromboembolism often remains elevated in such cases. (Level of Evidence: C) [1]
<Poll>
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIa Recommendation 2b for pharmacological cardioversion of atrial fibrillation should be:
CLASS I
CLASS IIa
CLASS IIb
CLASS III
</poll>
3. For patients with atrial flutter undergoing cardioversion, anticoagulation can be beneficial according to the recommendations as for patients with AF. (Level of Evidence: C) [1]
<Poll>
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIa Recommendation 3 for pharmacological cardioversion of atrial fibrillation should be:
CLASS I
CLASS IIa
CLASS IIb
CLASS III
</poll>
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation- Executive Summary: executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidlines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006; 114: 700-752. PMID 16908781